AVBP

10.5206.57%
CW

Christian W. Nolet

Independent Director

Mr. Christian W. Nolet, C.P.A. (Retired), also known as Chris, serves as an Independent Director at ArriVent Biopharma, Inc. since September 2023. He has been Director at Ambrx, Inc. since February 2021. He served as Director at Ambrx Biopharma Inc. since January 2021 until November 16, 2021. He served as a Director at PolarityTE Inc. since April 2020 until January 14, 2023. Mr. Nolet served as Director of Viela Bio, Inc. since August 19, 2019 until March 2021. Mr. Nolet was Independent Director of Revance Therapeutics, Inc. since July 16, 2019 until February 2025. Mr. Nolet served as West Region Life Sciences Industry Leader & Partner at Ernst & Young LLP (EY) since November 2001 to June 2019. In addition to serving clients, his responsibilities included leading West Region EY Life Sciences Industry Group and served as a Member of the Global EY Life Sciences Executive Leadership Group, which established policies and operating strategies for EY Life Sciences practice worldwide. Prior to joining EY, Mr. Nolet was a Partner at PricewaterhouseCoopers LLP since 1991 until 2001, where he led the Life Sciences practice in the western U.S. Previously, his emerging Companies Selection of the Biotechnology Innovation Organization (BIO) and was also active in supporting the need for patient access to innovative new therapies. He has testified before Congress with Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research (CDER), regarding the need for FDA reform. He served as an Independent Director of Jasper Therapeutics, Inc. since September 2021 until May 15, 2026. He served on the School of Accountancy Advisory Board at his alma mater San Diego State University. He has a B.S. in Accounting from San Diego State University and retired California Certified Public Accountant. He is former Member of the American Institute of CPAs and the California Society of CPAs.

Positions